S
EGRX

SignatureFD’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

SignatureFD’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-394
Closed -$7.66K – 3333
2023
Q2 		$7.66K Sell
394
-1,167
-75% -$27.7K ﹤0.01% 2349
2023
Q1 		$44.3K Buy
1,561
+1,036
+197% +$30.8K ﹤0.01% 1456
2022
Q4 		$15.3K Buy
525
+59
+13% +$1.88K ﹤0.01% 1938
2022
Q3 		$12K Sell
466
-225
-33% -$8.26K ﹤0.01% 2012
2022
Q2 		$31K Buy
691
+544
+370% +$25K ﹤0.01% 1556
2022
Q1 		$7K Buy
147
+59
+67% +$2.83K ﹤0.01% 2370
2021
Q4 		$4K Sell
88
-35
-28% -$1.81K ﹤0.01% 2528
2021
Q3 		$7K Buy
123
+12
+11% +$590 ﹤0.01% 2260
2021
Q2 		$5K Buy
111
+19
+21% +$784 ﹤0.01% 2315
2021
Q1 		$4K Sell
92
-3
-3% -$139 ﹤0.01% 2286
2020
Q4 		$4K Hold
95
– – ﹤0.01% 2079
2020
Q3 		$4K Buy
95
+74
+352% +$3.24K ﹤0.01% 2017
2020
Q2 		$1K Buy
+21
New +$1.05K ﹤0.01% 2420

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SignatureFD's EGRX Position: Q3 2023 in Review

SignatureFD sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 394 shares — an estimated $7.66K sold.

SignatureFD first reported a position in EGRX in Q2 2020 and held it in 13 quarters. The position peaked at $44.3K in Q1 2023. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • SignatureFD reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • SignatureFD sold 394 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $7.66K.
  • SignatureFD first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2020 and held it in 13 quarters.
  • SignatureFD's Eagle Pharmaceuticals, Inc. position peaked at $44.3K in Q1 2023.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on SignatureFD's 13F filing for Q3 2023, filed 3 Nov 2023.